GlassScriptPhysician profile
Luisito C Gonzales
NPI 1164425997
$11,409.61
in general payments reported to CMS, 2019-2025
42 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $700 · 2021: $1,556 · 2022: $1,945 · 2023: $2,087 · 2024: $2,052 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,225.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,177.57 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,158.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,053.72 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $1,052.29 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $952.57 | 2019-2025 | Jardiance |
| Amgen INC. | $716.17 | 2019-2024 | Repatha |
| Pfizer INC. | $590.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $581.87 | 2019-2024 | Farxiga, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $464.47 | 2021-2025 | |
| Shockwave Medical, INC | $375.83 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Actelion Pharmaceuticals US, INC. | $366.73 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Abbott Laboratories | $323.25 | 2019-2025 | Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $310.63 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $294.73 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $291.05 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luisito Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.